Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy

Area of Science:

• Hematology
• Infectious Diseases
• Oncology

Background:

• Micafungin is an established prophylactic antifungal agent for hematologic diseases.
• This study evaluates micafungin's efficacy and safety in acute leukemia patients during induction chemotherapy.
• Comparison with prophylactic posaconazole in acute myeloid leukemia (AML) patients was also performed.

Purpose of the Study:

• To assess the efficacy and safety of prophylactic micafungin in acute leukemia patients receiving induction chemotherapy.
• To compare micafungin with posaconazole for antifungal prophylaxis in AML patients.

Main Methods:

• Prospective trial involving medically fit patients with newly diagnosed acute leukemia.
• Micafungin (50 mg IV daily) administered from chemotherapy initiation until neutrophil recovery, suspected fungal infection, or toxicity.
• Primary endpoint: incidence of invasive fungal infection; Secondary endpoints: adverse events and mortality.

Main Results:

• Low incidence of invasive fungal infection (1.5% proven, 3.1% possible) in 65 patients.
• Adverse events (liver function abnormality, allergic reaction) were tolerable in 4.6% of patients.
• Outcomes in AML patients treated with micafungin were similar to those treated with posaconazole regarding fungal infections, discontinuation, and safety.

Conclusions:

• Prophylactic micafungin demonstrates safety and efficacy in acute leukemia patients undergoing induction chemotherapy.
• Micafungin serves as a viable prophylactic antifungal option for AML patients during induction chemotherapy, with outcomes comparable to posaconazole.